James K. McCloskey II, MD, was named Division Chief of the Division of Leukemia at Hackensack Meridian John Theurer Cancer Center (JTCC), part of Hackensack University Medical Center. Dr. McCloskey previously served as Interim Chief for the Division of Leukemia and will continue in his role as Director for the Program for Myeloproliferative Neoplasms at JTCC.
Dr. McCloskey specializes in the care of patients with acute leukemia, myelodysplastic syndromes, and myeloproliferative diseases. Before his appointment at JTCC, he was Chief Fellow in the Department of Hematology and Oncology at Georgetown University Hospital, where he also completed his residency. He earned his medical degree from Georgetown University School of Medicine. His research interests focus on developmental therapeutics for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes, and myeloproliferative disorders (including chronic myeloid leukemia).
“I would like to congratulate Dr. McCloskey and welcome him in his new role at JTCC,’’ said Mark Sparta, MPA, President and Chief Hospital Executive, Hackensack University Medical Center. “Dr. McCloskey’s research contributions have advanced the field of leukemia care, and we are proud that he is now leading our leukemia care team.”
“I am honored to be named Division Chief of the Division of Leukemia,” said Dr. McCloskey. “I am grateful to be part of an incredible team and look forward to continuing to build a program where we can offer our patients personalized, compassionate, and cutting-edge care.”
A Wealth of Research Experience
Dr. McCloskey has extensive research experience, serving as primary investigator on multiple clinical trials, including those evaluating IDH inhibitors in AML, novel therapies for myelodysplastic syndromes, and pacritinib for patients with myelofibrosis. He has authored or coauthored numerous publications, including book chapters, reviews, and abstracts. He has published research on the treatment of patients with adolescent ALL with pediatric-inspired induction regimens, as well as the outcomes of patients with AML with monocytic differentiation.
Dr. McCloskey has presented a range of clinical work at major medical conferences, including meetings of the American Society of Hematology, ASCO, Georgetown University Research Day, and the Society of Comparative and Integrative Biology. His research was published in Blood, Advances in Clinical Oncology, OncoTargets and Therapy, and Breast Cancer Research and Treatment.
“Dr. McCloskey, who joined us from Georgetown Lombardi Comprehensive Cancer Center a few years ago, has a true passion for leukemia, including a particular interest for precision medicine in AML and other myeloproliferative disorders,” said Andre Goy, MD, MS, Physician-in-Chief, Hackensack Meridian Health, Oncology Care Transformation Service. “Jim has provided crucial leadership for the division and helped to spur tremendous growth in providing high-quality care to our patients. We are excited for the future of our Division of Leukemia under his direction.”
